Miniatura

Fitxers

emmm.202113929.pdf (7.04 MB)

Tipus de document

Article

Versió

Versió publicada

Data de publicació

2021-08-11

Llicència de publicació

cc by (c) Herranz, Carmen et al., 2021
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/179910

Histamine signaling and metabolism identify potential biomarkers and therapies for lymphangioleiomyomatosis

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.15252/emmm.202113929

Resum

Inhibition of mTOR is the standard of care for lymphangioleiomyomatosis (LAM). However, this therapy has variable tolerability and some patients show progressive decline of lung function despite treatment. LAM diagnosis and monitoring can also be challenging due to the heterogeneity of symptoms and insufficiency of non-invasive tests. Here, we propose monoamine-derived biomarkers that provide preclinical evidence for novel therapeutic approaches. The major histamine-derived metabolite methylimidazoleacetic acid (MIAA) is relatively more abundant in LAM plasma, and MIAA values are independent of VEGF-D. Higher levels of histamine are associated with poorer lung function and greater disease burden. Molecular and cellular analyses, and metabolic profiling confirmed active histamine signaling and metabolism. LAM tumorigenesis is reduced using approved drugs targeting monoamine oxidases A/B (clorgyline and rasagiline) or histamine H1 receptor (loratadine), and loratadine synergizes with rapamycin. Depletion of Maoa or Hrh1 expression, and administration of an L-histidine analog, or a low L-histidine diet, also reduce LAM tumorigenesis. These findings extend our knowledge of LAM biology and suggest possible ways of improving disease management.

Matèries

Marcadors bioquímics, Histamina, Terapèutica

Matèries (anglès)

Biochemical markers, Histamine, Therapeutics

Citació

Col·leccions

Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))
Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)
Articles publicats en revistes (Patologia i Terapèutica Experimental)

Citació

HERRANZ, Carmen, MATEO GONZÁLEZ, Francesca, BAIGES, Alexandra, RUIZ DE GARIBAY, Gorka, JUNZA MARTÍNEZ, Alexandra, JOHNSON, Simon r, MILLER, Suzanne, GARCÍA, Nadia, CAPELLADES, Jordi, GÓMEZ, Antonio, VIDAL, August, PALOMERO, Luis, ESPÍN, Roderic, EXTREMERA, Ana i., BLOMMAERT, Eline, REVILLA LÓPEZ, Eva, SAEZ, Berta, GÓMEZ OLLÉS, Susana, ANCOCHEA, Julio, VALENZUELA, Claudia, ALONSO, Tamara, USSETTI, María piedad, LAPORTA, Rosalía, XAUBET MIR, Antonio, RODRÍGUEZ PORTAL, Jose antonio, MONTES WORBOYS, Ana, MACHAHUA, Carlos, BORDAS MARTÍNEZ, Jaume, MENENDEZ, Javier a., CRUZADO, Josep ma., GUITERAS, Roser, BONTOUX, Christophe, LA MOTTA, Concettina, NOGUERA CASTELLS, Aleix, MANCINO, Mario, LASTRA, Enrique, RIGO BONNIN, Raúl, PERALES, Jose c., VIÑALS CANALS, Francesc, LAHIGUERA, Alvaro, ZHANG, Xiaohu, CUADRAS, Daniel, MOORSEL, Coline h. m., VIS, Joanne j., QUANJEL, Marian j. r., FILIPPAKIS, Harilaos, HAKEM, Razq, GORRINI, Chiara, FERRER, Marc, UGUN KLUSEK, Aslihan, BILLETT, Ellen, RADZIKOWSKA, Elżbieta, CASANOVA, Álvaro, MOLINA MOLINA, María, ROMAN, Antonio, YANES, Oscar, PUJANA GENESTAR, M. ángel. Histamine signaling and metabolism identify potential biomarkers and therapies for lymphangioleiomyomatosis. _EMBO Molecular Medicine_. 2021. Vol. 13, núm. 9, pàgs. e13929. [consulta: 14 de gener de 2026]. [Disponible a: https://hdl.handle.net/2445/179910]

Exportar metadades

JSON - METS

Compartir registre